Literature DB >> 33775563

Mesopancreatic excision for pancreatic ductal adenocarcinoma improves local disease control and survival.

S-A Safi1, L Haeberle2, G Fluegen1, N Lehwald-Tywuschik1, A Krieg1, V Keitel3, T Luedde3, I Esposito2, A Rehders1, W T Knoefel4.   

Abstract

BACKGROUND: Survival in ductal adenocarcinoma of the pancreatic head (hPDAC) is poor. After implementation of the circumferential resection margin (CRM) into standard histopathological evaluation, the margin negative resection rate has drastically dropped. However, the impact of surgical radicality on survival and the influence of malignant infiltration of the mesopancreatic fat remains unclear. At our institution, a standardized dissection of the mesopancreatic lamina and peri-pancreatic vessels are obligatory components of radical pancreatoduodenectomy. The aim of our study was to histopathologically analyze mesopancreatic tumor infiltration and the influence of CRM-evaluated resection margin on relapse-free and overall survival.
METHOD: Clinicopathological and survival parameters of 264 consecutive patients who underwent surgery for hPDAC were evaluated.
RESULTS: The rate of R0 resection R0(CRM-) was 48.5%, after the implementation of CRM. Mesopancreatic fat infiltration was evident in 78.4% of all consecutively treated patients. Patients with mesopancreatic fat infiltration were prone to lymphatic metastases (N1 and N2) and had a higher rate of positive resection margin (R1/R0(CRM+)). In multivariate analysis, only R0 resection was shown to be an independent prognostic parameter. Local recurrence was diagnosed in only 21.1% and was significantly lower in patients with R0(CRM-) resected hPDACs (10.9%, p < 0.001).
CONCLUSION: Mesopancreatic excision is justified, since mesopancreatic fat invasion was evident in the majority of our patients. It is associated with a significantly improved local tumor control as well as longer relapse-free and overall survival.
Copyright © 2021 IAP and EPC. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CRM; Ductal adenocarcinoma of the pancreas; Mesopancreatic excision; PDAC; Pancreatic cancer; Peripancreatic tissue; Survival outcome

Mesh:

Year:  2021        PMID: 33775563     DOI: 10.1016/j.pan.2021.02.024

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  4 in total

1.  Neoadjuvant Treatment Lowers the Risk of Mesopancreatic Fat Infiltration and Local Recurrence in Patients with Pancreatic Cancer.

Authors:  Sami-Alexander Safi; Lena Haeberle; Alexander Rehders; Stephen Fung; Sascha Vaghiri; Christoph Roderburg; Tom Luedde; Farid Ziayee; Irene Esposito; Georg Fluegen; Wolfram Trudo Knoefel
Journal:  Cancers (Basel)       Date:  2021-12-23       Impact factor: 6.639

Review 2.  Advances in Pancreatic Ductal Adenocarcinoma Treatment.

Authors:  Eric M Anderson; Shant Thomassian; Jun Gong; Andrew Hendifar; Arsen Osipov
Journal:  Cancers (Basel)       Date:  2021-11-03       Impact factor: 6.639

3.  Genetic Alterations Predict Long-Term Survival in Ductal Adenocarcinoma of the Pancreatic Head.

Authors:  Sami-Alexander Safi; Lena Haeberle; Wolfgang Goering; Verena Keitel; Georg Fluegen; Nikolas Stoecklein; Alexander Rehders; Wolfram Trudo Knoefel; Irene Esposito
Journal:  Cancers (Basel)       Date:  2022-02-08       Impact factor: 6.639

4.  Clinicopathological and Prognostic Value of Survivin Expression in Surgically Resected Pancreatic Ductal Adenocarcinoma.

Authors:  Christian Vay; Shahrooz Babaei; Sami-Alexander Safi; Levent Dizdar; Alexander Rehders; Lena Haeberle; Christoph Roderburg; Sven H Loosen; Irene Esposito; Wolfram T Knoefel; Andreas Krieg
Journal:  Cancers (Basel)       Date:  2022-07-18       Impact factor: 6.575

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.